RESUMEN
The hallmark of autoimmune arthritis is the preceding autoantibody production and the following synovial inflammation with hyperplasia and tissue destruction of the joints. The joint inflammation is mediated not only by effector lymphocytes and auto-antibodies but also chronic activation of innate immunity, particularly promoted by the danger-associated molecular patterns (DAMPs). Here we show that apoptosis inhibitor of macrophage (AIM, also called CD5L) protein regulates arthritis by promoting removal of lesional DAMPs both physiologically and therapeutically. When the autoimmune arthritis was promoted by injecting a cocktail of anti-collagen antibodies without type-II collagen immunization, AIM-deficient (AIM-/-) mice exhibited more exacerbated and sustained swelling at multiple joints with greater synovial hyperplasia and bone erosion than wild-type mice. Administration of recombinant AIM (rAIM) reduced S100A8/9, a major DAMP known to be involved in arthritis progression, and decreased various inflammatory cytokines at the lesions in antibody-injected AIM-/- mice, leading to marked prevention of arthritis symptoms. In human rheumatoid arthritis (RA) patients, AIM was more activated via dissociating from IgM-pentamer in response to DAMPs-mediated inflammation both in serum and synovial fluid than in healthy individuals or non-autoimmune osteoarthritis patients, suggesting a disease-regulatory potency of AIM also in human RA patients. Thus, our study implied a therapeutic availability of rAIM to prevent arthritis symptoms targeting DAMPs.
Asunto(s)
Artritis Experimental , Artritis Reumatoide , Enfermedades Autoinmunes , Animales , Humanos , Ratones , Proteínas Reguladoras de la Apoptosis/metabolismo , Enfermedades Autoinmunes/patología , Hiperplasia/metabolismo , Hiperplasia/patología , Inflamación/metabolismo , Receptores Depuradores/metabolismo , Membrana Sinovial/patologíaRESUMEN
Bone loss due to smoking represents a major risk factor for fractures and bone osteoporosis. Signaling through the aryl hydrocarbon receptor (AhR) and its ligands contributes to both bone homeostasis and inflammatory diseases. It remains unclear whether the same AhR signaling axis affects the temporomandibular joint (TMJ). The aim of this study was to investigate possible mechanisms which mediate bone loss in the TMJ due to smoking. In particular, whether benzo[a]pyrene (B[a]P), a carcinogen of tobacco smoke, induces expression of the AhR target gene, Cyp1a1, in mandibular condyles. Possible functions of an endogenous ligand of FICZ, were also investigated in a TMJ-osteoarthritis (OA) mouse model. B[a]P was administered orally to wild-type and AhR-/- mice and bone metabolism was subsequently examined. TMJ-OA was induced in wild-type mice with forceful opening of the mouth. Therapeutic functions of FICZ were detected with µCT and histology. Exposure to B[a]P accelerated bone loss in the mandibular subchondral bone. This bone loss manifested with osteoclastic bone resorption and upregulated expression of Cyp1a1 in an AhR-dependent manner. In a mouse model of TMJ-OA, FICZ exhibited a dose-dependent rescue of mandibular subchondral bone loss by repressing osteoclast activity. Meanwhile, in vitro, pre-treatment with FICZ reduced RANKL-mediated osteoclastogenesis. B[a]P regulates mandibular subchondral bone metabolism via the Cyp1a1. The AhR ligand, FICZ, can prevent TMJ-OA by regulating osteoclast differentiation.
Asunto(s)
Benzo(a)pireno/efectos adversos , Carbazoles/farmacología , Carbazoles/uso terapéutico , Citocromo P-450 CYP1A1/metabolismo , Osteoartritis/genética , Osteoartritis/prevención & control , Receptores de Hidrocarburo de Aril/metabolismo , Transducción de Señal/genética , Transducción de Señal/fisiología , Articulación Temporomandibular/metabolismo , Animales , Resorción Ósea/tratamiento farmacológico , Resorción Ósea/etiología , Citocromo P-450 CYP1A1/genética , Modelos Animales de Enfermedad , Reducción Gradual de Medicamentos , Expresión Génica/efectos de los fármacos , Ratones Endogámicos C57BL , Osteoartritis/metabolismo , Osteogénesis/efectos de los fármacos , Receptores de Hidrocarburo de Aril/genética , Fumar/efectos adversosRESUMEN
There is increasing evidence that platelets participate in multiple pathophysiological processes other than thrombosis and hemostasis, such as immunity, inflammation, embryonic development, and cancer progression. A recent study revealed that heme (hemin)-activated platelets induce macrophage extracellular traps (METs) and exacerbate rhabdomyolysis-induced acute kidney injury (RAKI); however, how hemin activates platelets remains unclear. Here, we report that both C-type lectin-like receptor-2 (CLEC-2) and glycoprotein VI (GPVI) are platelet hemin receptors and are involved in the exacerbation of RAKI. We investigated hemin-induced platelet aggregation in humans and mice, binding of hemin to CLEC-2 and GPVI, the RAKI-associated phenotype in a mouse model, and in vitro MET formation. Using western blotting and surface plasmon resonance, we showed that hemin activates human platelets by stimulating the phosphorylation of SYK and PLCγ2 and directly binding to both CLEC-2 and GPVI. Furthermore, hemin-induced murine platelet aggregation was partially reduced in CLEC-2-depleted and FcRγ-deficient (equivalent to GPVI-deficient) platelets and almost completely inhibited in CLEC-2-depleted FcRγ-deficient (double-knockout) platelets. In addition, hemin-induced murine platelet aggregation was inhibited by the CLEC-2 inhibitor cobalt hematoporphyrin or GPVI antibody (JAQ-1). Renal dysfunction, tubular injury, and MET formation were attenuated in double-knockout RAKI mice. Furthermore, in vitro MET formation assay showed that the downstream signaling pathway of CLEC-2 and GPVI is involved in MET formation. We propose that both CLEC-2 and GPVI in platelets play an important role in RAKI development.
Asunto(s)
Lesión Renal Aguda , Rabdomiólisis , Lesión Renal Aguda/etiología , Animales , Plaquetas , Femenino , Hemo , Lectinas Tipo C/genética , Ratones , Glicoproteínas de Membrana Plaquetaria/genética , EmbarazoRESUMEN
To develop a noninvasive sample collection method for genotyping, we compared PCR products from samples collected from neonates using five different brands of adhesive tape. Next, the youngest application age to distinguish genotypes was established. The tapes were applied on the backs of rats on postnatal day (PND) 10. DNA extracts from two brands provided clear PCR products that enabled genotype identification. The youngest age for distinguishing genotypes was PND 5; however, the youngest age that provided accurate results was PND 7. Thus, the present method allows for genotyping during the neonatal period without invasive burden and may improve animal welfare by refining.